La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

2cureX Gestion

Gestion contrôle des critères 2/4

Le PDG 2cureX's est Ole Thastrup, nommé en Jan2006, a un mandat de 18.58 ans. détient directement 23.8% des actions de la société, d'une valeur de SEK 2.05M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.5 ans et 2.9 ans.

Informations clés

Ole Thastrup

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	18.6yrs
Propriété du PDG	23.8%
Durée moyenne d'occupation des postes de direction	3.5yrs
Durée moyenne du mandat des membres du conseil d'administration	2.9yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Ole Thastrup a-t-elle évolué par rapport aux bénéfices de 2cureX?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Dec 31 2023	n/a	n/a	-SEK 33m
Sep 30 2023	n/a	n/a	-SEK 33m
Jun 30 2023	n/a	n/a	-SEK 31m
Mar 31 2023	n/a	n/a	-SEK 29m
Dec 31 2022	SEK 150k	n/a	-SEK 30m
Sep 30 2022	n/a	n/a	-SEK 29m
Jun 30 2022	n/a	n/a	-SEK 26m
Mar 31 2022	n/a	n/a	-SEK 25m
Dec 31 2021	SEK 150k	n/a	-SEK 19m
Sep 30 2021	n/a	n/a	-SEK 15m
Jun 30 2021	n/a	n/a	-SEK 10m
Mar 31 2021	n/a	n/a	-SEK 8m
Dec 31 2020	SEK 2m	SEK 2m	-SEK 7m
Sep 30 2020	n/a	n/a	-SEK 7m
Jun 30 2020	n/a	n/a	-SEK 8m
Mar 31 2020	n/a	n/a	-SEK 8m
Dec 31 2019	SEK 2m	SEK 2m	-SEK 8m
Sep 30 2019	n/a	n/a	-SEK 6m
Jun 30 2019	n/a	n/a	-SEK 6m
Mar 31 2019	n/a	n/a	-SEK 6m
Dec 31 2018	SEK 2m	SEK 2m	-SEK 7m

Rémunération vs marché: Données insuffisantes pour établir si la rémunération totale de Ole est raisonnable par rapport à des entreprises de taille similaire sur le marché Swedish.

Rémunération et revenus: La rémunération de Ole a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Ole Thastrup (71 yo)

18.6yrs

Titularisation

SEK 150,000

Compensation

Mr. Ole Thastrup is CEO of 2cureX AB (publ) since June 2024 and serves as it's Vice Chairman of the Board since January 01, 2024 and served as the Chief Scientific Officer since January 2021 until January...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Ole Thastrup	Co-Founder	18.6yrs	SEK 150.00k	23.8% SEK 1.8m
Grith Hagel	Co-Founder	no data	pas de données	3.87% SEK 287.7k
Kenneth Johansen	Chief Financial Officer	3.5yrs	pas de données	0.023% SEK 1.7k
Jacob Thastrup	Chief Technology Officer	less than a year	pas de données	0.062% SEK 4.6k
Manuel Fernandez	Director Quality & Regulatory Affairs	no data	pas de données	pas de données

3.5yrs

Durée moyenne de l'emploi

56.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 2CUREX est considérée comme expérimentée (ancienneté moyenne 3.5 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Ole Thastrup	Co-Founder	18.6yrs	SEK 150.00k	23.8% SEK 1.8m
Grith Hagel	Co-Founder	less than a year	pas de données	3.87% SEK 287.7k
John Marshall	Member of Clinical Advisory Board	3.1yrs	pas de données	pas de données
Jesus Garcia-Foncillas	Member of Clinical Advisory Board	3.1yrs	pas de données	pas de données
Andrew Beggs	Member of Clinical Advisory Board	2.8yrs	pas de données	pas de données
Tonni Bulow-Nielsen	Chairman of the Board	less than a year	pas de données	pas de données

2.9yrs

Durée moyenne de l'emploi

Conseil d'administration expérimenté: Les membres du conseil d'administration de 2CUREX ne sont pas considérés comme expérimentés (ancienneté moyenne 2.9 ans), ce qui suggère un nouveau conseil d'administration.

2cureX Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

2cureX AB (publ) Announces CEO Changes

No independent directors

2curex AB (publ) Elects Grith Hagel as a New Board Member

2cureX AB (publ), Annual General Meeting, May 23, 2024

2Curex AB (Publ) Appoints Tonni Bülow-Nielsen as Board Member and Chairman

Chief Executive Officer recently bought kr136k worth of stock

Recent updates

2cureX AB (publ) Announces CEO Changes

2cureX AB (publ) to Report Q4, 2024 Results on Feb 20, 2025

No independent directors

2curex AB (publ) Elects Grith Hagel as a New Board Member

Full year 2023 earnings released: kr1.75 loss per share (vs kr1.69 loss in FY 2022)

2cureX AB (publ), Annual General Meeting, May 23, 2024

2cureX AB (publ) to Report Q2, 2024 Results on Aug 22, 2024

2cureX AB (publ) Receives Ethical Approval for HIPEC Clinical Trial

Third quarter 2023 earnings released: kr0.58 loss per share (vs kr0.47 loss in 3Q 2022)

2Curex AB (Publ) Appoints Tonni Bülow-Nielsen as Board Member and Chairman

New minor risk - Share price stability

2curex Launches Its First Two IndiTreat® Products Ce-Marked Under the New Ivd Regulation

New major risk - Financial position

First quarter 2023 earnings released: kr0.43 loss per share (vs kr0.45 loss in 1Q 2022)

Chief Executive Officer recently bought kr136k worth of stock

Chief Executive Officer recently bought kr136k worth of stock

Full year 2022 earnings released: kr1.69 loss per share (vs kr1.15 loss in FY 2021)

Full year 2022 earnings released: kr1.69 loss per share (vs kr1.15 loss in FY 2021)

2cureX AB (publ) Appoints Michel Klimkeit to Board of Director

2cureX AB (publ) to Report Q4, 2023 Results on Feb 22, 2024

Third quarter 2022 earnings released: kr0.47 loss per share (vs kr0.31 loss in 3Q 2021)

High number of new and inexperienced directors

2cureX AB (publ), Annual General Meeting, May 25, 2023

2cureX Announces Board Change

Chief Executive Officer recently bought kr84k worth of stock

We're Not Very Worried About 2cureX's (STO:2CUREX) Cash Burn Rate

2cureX AB (publ) Presents Inditreat® Clinical Results At the Society for Functional Precision Medicine

High number of new and inexperienced directors

Manuel Fernández Joins 2cureX as Director of Quality Assurance and Regulatory Affairs

2cureX AB (publ) Announces Management Changes

2cureX (STO:2CUREX) Is In A Good Position To Deliver On Growth Plans

2cureX Launches IndiTreat mCRC Start Test to Guide First Line Treatment

We're Not Very Worried About 2cureX's (STO:2CUREX) Cash Burn Rate

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

2cureX Announces New Development of the IndiTreat Technology Allows Prediction of Response to Anti-Angiogenic Drugs in Colorectal Cancer

High number of new and inexperienced directors

We're Interested To See How 2cureX (STO:2CUREX) Uses Its Cash Hoard To Grow

2Curex AB (Publ) Clinical Partner, University Hospital Vejle, Presents Positive Results of Thnditreat®-Guided Clinicaical Trial in Third Line Metastatic Colorectal Cancer At the Asco 2021 Annual Meeting

Co-Founder exercised options to buy kr7.6m worth of stock.

2cureX AB (publ) Announces Clinical Trial of Inditreat®-Guided Treatment of Metastatic Colorectal Cancer

2cureX AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022

Shareholders Of 2cureX (STO:2CUREX) Must Be Happy With Their 280% Total Return

2cureX AB's IndiTreat® Selected to Prestigious Multinational Ovarian Cancer Project

New 90-day high: kr22.60

Chief Financial Officer has left the company

2cureX Appoints Kenneth Graabek Johansen as New CFO, Effective 1 February 2021

2cureX Announces Last Patient Treated in the World's First Interventional Trial with 3D Microtumors as Guide for Choice of Cancer Treatment

New 90-day high: kr17.65

2cureX Announces Management Changes

2cureX AB (publ), Annual General Meeting, May 27, 2021

How Does 2cureX's (STO:2CUREX) CEO Salary Compare to Peers?

New 90-day low: kr16.25

2cureX Announces Last Patient Successfully Enrolled in the Worlds First Interventional Trial with 3D Microtumors as Guide for Choice of Cancer Treatment

New 90-day low: kr17.30

2cureX launches world's first CE-marked microtumor test service

New 90-day high - kr22.50

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration